{"id":"NCT00838201","sponsor":"Amgen","briefTitle":"Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer","officialTitle":"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02-01","primaryCompletion":"2012-05-03","completion":"2012-05-03","firstPosted":"2009-02-06","resultsPosted":"2013-09-24","lastUpdate":"2018-10-18"},"enrollment":384,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cancer","Carcinoma","Castrate-Resistant Prostate Cancer","Prostate Cancer","Tumors"],"interventions":[{"type":"DRUG","name":"Denosumab","otherNames":[]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 Amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab for non-metastatic prostate cancer.","primaryOutcome":{"measure":"Overall Survival Through Month 24","timeFrame":"24 months","effectByArm":[{"arm":"Placebo/Denosumab 60 mg SC Q6M","deltaMin":174,"sd":null},{"arm":"Denosumab/Denosumab 60 mg SC Q6M","deltaMin":184,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":74,"countries":["United States","Canada","Finland","Hungary","Mexico","Poland"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":185},"commonTop":["Constipation","Arthralgia","Pain in extremity","Nausea","Back pain"]}}